19 November 2021 - Theradaptive announced that the U.S. FDA has granted breakthrough medical device designation to its Osteo-Adapt SP Spinal Fusion implant indicated for transforaminal lumbar interbody spinal fusion to treat degenerative disc disease, spondylolisthesis, or retrolisthesis.

Theradaptive's regenerative implants are best in class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications. The new technology enables superior outcomes and safety, and greatly improved ease of use.

Read Therapadaptive press release